The law › Title 21, Food and Drugs › Chapter 9
21 U.S.C. 360bbb-8c: Patient participation in medical product discussion
Created in 2012 by the Food and Drug Administration Safety and Innovation Act (Public Law 112-144). Changed by 2 later laws. 1 bill in this Congress would change it.
- past change
- enacted this Congress
- proposed
This Congress
- H.R. 9877 Health Equity and Accountability Act of 2026 · introduced · would change (b)
How it got here
2017
- Pub. L. 115–52 substituted "impact (including physical and psychosocial impacts) of such disease or condition, or a related therapy or clinical investigation" for "impact of such disease or condition, or a related therapy,". (FDA Reauthorization Act of 2017) Law text · (c)
2016
- Pub. L. 114–255, §3001(1), (2), substituted "Patient engagement in drugs and devices" for "In general" in subsec. heading, designated existing provisions as par. (1) and inserted par. heading, redesignated former pars. (1) and (2) as subpars. (A) and (B), respectively, of par. (1), red… (21st Century Cures Act) Law text · (a)
- Pub. L. 114–255, §3001(3), added subsecs. (b) and (c). Former subsecs. (b) and (c) redesignated pars. (2) and (3), respectively, of subsec. (a). (21st Century Cures Act) Law text · (b), (c)
- Pub. L. 114–255, §3001(2), redesignated subsecs. (d) and (e) as pars. (4) and (5), respectively, of subsec. (a). (21st Century Cures Act) Law text · (d), (e)
Text, outline and history from the official U.S. Code (2024 edition) on GovInfo, published by the Office of the Law Revision Counsel. Changes made after that edition appear under This Congress.